Catalysts for CALQUENCE
13 tracked
Apr 30, 2026
phase 1 2 completion
AstraZeneca Plc — Calquence (Phase I/II Trial Completion)
CALQUENCE
→
Feb 19, 2026
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Feb 19, 2026
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Jan 16, 2025
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Jan 16, 2025
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Jun 5, 2024
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Jun 5, 2024
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Aug 3, 2022
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Aug 3, 2022
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Mar 24, 2022
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Nov 21, 2019
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Nov 21, 2019
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Oct 31, 2017
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→